NCT02996448: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 336 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02996448 |
|---|---|
| Title | A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 17, 2016 |
| Completion date | July 22, 2018 |
| Required reporting date | July 22, 2019, midnight |
| Actual reporting date | June 22, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 336 |